Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Duca

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Therapeutic Advances in Medical Oncology|August 4, 2022
Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer centerGiovanni Fucà, Mara Lecchi, Chiara Maura Ciniselli, et al.
JCO Precision Oncology|July 24, 2023
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient CareAndrea Vingiani, Luca Agnelli, Matteo Duca, et al.
Cancer Discovery|February 11, 2017
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Therapeutic Advances in Medical Oncology|August 4, 2022
Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer centerGiovanni Fucà, Mara Lecchi, Chiara Maura Ciniselli, et al.
JCO Precision Oncology|July 24, 2023
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient CareAndrea Vingiani, Luca Agnelli, Matteo Duca, et al.
Cancer Discovery|February 11, 2017
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, et al.
Pageof 4